An Isolated Nucleic Acid Encoding a Truncated Actriib Fusion Protein
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 61/268,420, filed Jun 12, 2009. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,293,881 | An Isolated Nucleic Acid Encoding a Truncated Actriib Fusion Protein In force · High confidence UsedRemaining | Acceleron Pharma Inc. | In force | High confidence | ||
| US 9,745,559 | A Method for Decreasing the Body Fat Content in a Subject by Administering an Actriib Protein In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | ||
| US 10,358,633 | Method for Decreasing the Body Fat Content in a Subject by Administering an Actriib Protein In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 11,066,654 | Methods and Compositions for Reducing Serum Lipids In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 9,181,533 | Truncated Actriib-Fc Fusion Protein In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | ||
| Application 17/358,540 | Truncated Actriib-Fc Fusion Proteins Abandoned Abandoned Jan 8, 2024 | Acceleron Pharma Inc. | Abandoned | Abandoned Jan 8, 2024 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.